Specialties

Select category

Internal Medicine Oncology, Medical Family Medicine/General Practice Obstetrics & Gynecology Hematology Surgery, General Pediatrics Cardiology Allergy & Immunology Endocrinology, Diabetes, Metabolism Pulmonology Oncology, Radiation Oncology, Surgical Neurology Rheumatology Psychiatry Urology Emergency Medicine Dermatology Gastroenterology Geriatrics Radiology Ophthalmology Anesthesiology Pathology Surgery, Plastic Medical Genetics Hospitalist Residency Cardiology, Interventional All Specialties Hepatology Surgery, Neurologic Surgery, Orthopedic Nephrology Pain Medicine Neuromusculoskeletal Medicine & OMM Surgery, Colon & Rectal Physical Medicine & Rehabilitation Clinical Pharmacology Otolaryngology

Home
About HCN
Contact Us
Sources

Peer-influenced content. Sources you trust. No registration required. This is HCN.

Latest From The Journal of Clinical Investigation (JCI)

The Journal of Clinical Investigation (JCI)

Targeting Mutations in Cancer

Targeted therapy gene mutations may: (a) encode a protein that can be targeted in a manner distinct from the WT protein; (b) cause abnormal activation of a protein that is druggable but for which mutant-specific targeting has not been achieved; or (c) create novel molecular dependencies that are druggable. This article describe key examples of genetic drivers and associated modes of druggability, considers the clinical and research challenges in the field, and discusses new approaches to maximizing therapeutic benefit of targeted therapies.

Oncology, Medical May 18th 2022

Tags: GENE THERAPY SOLID TUMORS TARGETED THERAPIES

The Journal of Clinical Investigation (JCI)

PD-1 and ICOS Co-expression Identifies Tumor-reactive CD4 T Cells in Human Solid Tumors

The authors analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4 Th cells that appear to be directly involved in the anti-tumor immune response.

Oncology, Medical May 18th 2022

Tags: COLORECTAL CANCER (CRC) HEAD & NECK CANCER (HNC) IMMUNOTHERAPY SOLID TUMORS

The Journal of Clinical Investigation (JCI)

Expansion, Persistence, and Efficacy of Donor Memory-like NK Cells Infused for Post-transplant Relapse

Responses to conventional donor lymphocyte infusion for post-allogeneic hematopoietic cell transplantation relapse are typically poor. Natural killer cell-based therapy is a promising modality to treat post-HCT relapse. This ongoing phase I trial of adoptively transferred cytokine induced memory-like (CIML) NK cells in patients with myeloid malignancies relapsed after haploidentical HCT saw a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires.

Oncology, Medical April 5th 2022

Tags: CLONAL HEMATOPOIESIS (CH) HEMATOLOGY/ONCOLOGY TRANSPLANTATION

© Healthcare Communications Network
Privacy Policy
Do Not Sell My Personal Information